Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial

BackgroundImmunotherapy (Programmed cell death 1 blockade) has entered the ranks of advanced esophageal cancer first-line treatment; however, little is known about the efficacy of PD-1 inhibitor as neoadjuvant therapy in resectable esophageal squamous cell carcinoma (ESCC). We aim to evaluate the ac...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Zhi Zhang, Jinjun Ye, Hui Li, Dayong Gu, Mingyu Du, Dashan Ai, Wei Chen, Ying Fang, Xinyu Xu, Chenguang Bai, Kuaile Zhao, Guoren Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Subjects:	neoadjuvant sintilimab and chemotherapy resectable esophageal squamous cell carcinoma prospective
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1031171/full